Aesica’s high capacity manufacturing facility at its Queenborough, UK site has been successfully validated for commercial production. The company invested $45 million to expand commercial production for a solid dose medication used to treat Type 2 diabetes. The product is sold globally and is ready for worldwide export.   The expanded facility is capable of producing more than 1 billion tablets per year and was designed to accommodate potential future expansion to produce more than 2.5 billion t...